Efficacy and safety of mavrilimumab in subjects with rheumatoid arthritis - Wikidata - awgldk - TriplyDB

Efficacy and safety of mavrilimumab in subjects with rheumatoid arthritis

Efficacy and safety of mavrilimumab in subjects with rheumatoid arthritis

http://www.wikidata.org/entity/Q34317197

about

Type I/II cytokines, JAKs, and new strategies for treating autoimmune diseases Biologicals in rheumatoid arthritis: current and future Pivotal roles of GM-CSF in autoimmunity and inflammation Emerging Therapies for Rheumatoid Arthritis GM-CSF: An immune modulatory cytokine that can suppress autoimmunity Colony-stimulating factor (CSF) 1 receptor blockade reduces inflammation in human and murine models of rheumatoid arthritis Potential role of granulocyte-monocyte colony-stimulating factor in the progression of intracranial aneurysms.Bhlhe40 controls cytokine production by T cells and is essential for pathogenicity in autoimmune neuroinflammation.Identification of rheumatoid arthritis and osteoarthritis patients by transcriptome-based rule set generation.Future therapeutic targets in rheumatoid arthritis?T cell expression of granulocyte-macrophage colony-stimulating factor in juvenile arthritis is contingent upon Th17 plasticity.Granulocyte-macrophage colony-stimulating factor: not just another haematopoietic growth factor.Mavrilimumab: an evidence based review of its potential in the treatment of rheumatoid arthritis MOR103, a human monoclonal antibody to granulocyte-macrophage colony-stimulating factor, in the treatment of patients with moderate rheumatoid arthritis: results of a phase Ib/IIa randomised, double-blind, placebo-controlled, dose-escalation trial.Complementary action of granulocyte macrophage colony-stimulating factor and interleukin-17A induces interleukin-23, receptor activator of nuclear factor-κB ligand, and matrix metalloproteinases and drives bone and cartilage pathology in experimenta Dual Role of GM-CSF as a Pro-Inflammatory and a Regulatory Cytokine: Implications for Immune Therapy.CBP30, a selective CBP/p300 bromodomain inhibitor, suppresses human Th17 responses Preclinical characterisation of the GM-CSF receptor as a therapeutic target in rheumatoid arthritis.Optimizing Rheumatoid Arthritis Therapy: Using Objective Measures of Disease Activity to Guide Treatment.Systematic review and network meta-analysis of the efficacy and safety of tumour necrosis factor inhibitor-methotrexate combination therapy versus triple therapy in rheumatoid arthritis.Phase 1b randomized, double-blind study of namilumab, an anti-granulocyte macrophage colony-stimulating factor monoclonal antibody, in mild-to-moderate rheumatoid arthritis.Emerging cell and cytokine targets in rheumatoid arthritis.Cytokine networking of innate immunity cells: a potential target of therapy.Emerging immunotherapies for rheumatoid arthritis.Efficacy and safety implications of molecular constructs of biological agents for rheumatoid arthritis.Human Th1 dichotomy: origin, phenotype and biologic activities.GM-CSF as a target in inflammatory/autoimmune disease: current evidence and future therapeutic potential.The IL-23-IL-17 axis in inflammatory arthritis.The role of T regulatory cells in immunopathogenesis of myasthenia gravis: implications for therapeutics.Targeting Th17 Effector Cytokines for the Treatment of Autoimmune Diseases.Triple DMARD treatment in early rheumatoid arthritis modulates synovial T cell activation and plasmablast/plasma cell differentiation pathways.Targeting GM-CSF in inflammatory diseases.Cytokines in rheumatoid arthritis - shaping the immunological landscape.Old and new therapeutics for Rheumatoid Arthritis: in vivo models and drug development.Selected cytokine pathways in rheumatoid arthritis.Macrophage heterogeneity in the context of rheumatoid arthritis.Spotlight on mavrilimumab for the treatment of rheumatoid arthritis: evidence to date The barrier hypothesis and Oncostatin M: Restoration of epithelial barrier function as a novel therapeutic strategy for the treatment of type 2 inflammatory disease.GM-CSF signalling blockade and chemotherapeutic agents act in concert to inhibit the function of myeloid-derived suppressor cells in vitro.Therapeutic Targeting of the G-CSF Receptor Reduces Neutrophil Trafficking and Joint Inflammation in Antibody-Mediated Inflammatory Arthritis.

P2860

Q26775111-92867D91-A7B2-457F-90A5-65A38A7BF8B6 Q26780316-9F350086-1514-468F-A7D9-39838CD18336 Q26830824-A99E3F42-69BF-4B36-8DDB-D9F3F94DCB8B Q28078943-1D62C8BF-BF5B-455E-9900-CC8BC3A6A80D Q28080640-C748FFF5-D21F-4B38-9719-CDDAFAE00D51 Q28601432-52001EAF-4F71-4122-991D-CB3D34370C36 Q30361774-0EC7181C-079E-4135-A693-D36DAAE13D30 Q33592713-B3F8F85A-0D3A-44C6-8BE2-85B3782F0566 Q33766708-59BE5A92-D8AA-4502-A22A-4F196FACE1E7 Q33841419-9C8340EB-CF1C-40E9-8960-BB5498E2AC93 Q34310449-7B9C962A-A504-4EA9-B1DE-FAAE21B5976E Q34387000-4464D0D8-9F33-47EB-9F41-7510F04110D4 Q34411088-92C90D18-7491-4FD5-9DAB-1D703A13B611 Q35605418-0996A883-C443-4E9A-85A7-D7CBA269568E Q35834491-CB0A4FAC-3921-4EAC-99AD-A0C916E2705B Q35928330-32E3AA26-3B83-4D01-AC6E-1FD575EAC955 Q36008355-680B9A44-4A7C-4C5F-A03D-9CBB6345F449 Q36150157-D6A5154C-9626-4207-A76D-A5D4E970CF83 Q36257543-394A00E4-C036-45B7-80E9-C88F3F581EBD Q37587412-4131AD20-349C-4B49-A1E5-533592965F37 Q37690033-343593C6-3854-468A-8B54-379394798D30 Q38161794-94CF6654-5B38-4D97-B7E9-539346E8C899 Q38180799-5B820663-B89D-4063-BE3B-856E2D855F95 Q38188862-990EBD0C-2202-4E67-81DF-D68C463CDEE7 Q38203622-B2CAEC8A-8014-4073-A924-537B1CE55A0E Q38256942-FFA655EF-A566-4AC0-A764-B569E378EDB7 Q38369816-C98A4DF0-C457-40E1-BA38-BE19D4402F37 Q38439641-537E54FF-73A9-4277-9F2F-6184A66B8E1F Q38479391-840EA6D2-FC03-48EC-82F1-B3474D360CDE Q38584529-295F93CA-BFAC-4E42-8CCA-85E87C58E4F4 Q38597826-1BCBF265-9508-4373-BCD9-6A42728472CE Q38657999-21217BB9-9A5E-4590-9E77-86DC1E7E3CAA Q38666239-2002CF77-E96B-4DCD-8834-9C677CE2B5BC Q38697262-7D100F27-C208-49EC-9AEA-8BC41646A196 Q38755912-98169A47-CEAC-41A1-B8E0-441A90D27890 Q38844780-B23CB8FE-217F-45AA-B5AC-6C0624C6C9D8 Q38988087-86079452-BAC1-4150-9B84-DB78C61E8F8C Q39407129-D24F9FD6-FAF4-476E-9DF0-5ECA4389CC6E Q40032613-4ED73CCC-2F60-4836-8465-9A17D257CBB4 Q40468456-ECD50D87-7F79-40C6-95BF-2F21136D0B95

P2860

Efficacy and safety of mavrilimumab in subjects with rheumatoid arthritis

http://www.wikidata.org/entity/Q34317197

description

2012 nî lūn-bûn

@nan

2012 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Efficacy and safety of mavrilimumab in subjects with rheumatoid arthritis

@ast

Efficacy and safety of mavrilimumab in subjects with rheumatoid arthritis

@en

Efficacy and safety of mavrilimumab in subjects with rheumatoid arthritis

@nl

type

label

Efficacy and safety of mavrilimumab in subjects with rheumatoid arthritis

@ast

Efficacy and safety of mavrilimumab in subjects with rheumatoid arthritis

@en

Efficacy and safety of mavrilimumab in subjects with rheumatoid arthritis

@nl

prefLabel

Efficacy and safety of mavrilimumab in subjects with rheumatoid arthritis

@ast

Efficacy and safety of mavrilimumab in subjects with rheumatoid arthritis

@en

Efficacy and safety of mavrilimumab in subjects with rheumatoid arthritis

@nl

P1433

Q34317197-952017F5-78D0-43B6-B3D9-3BD5FDD06BEC

P1476

Q34317197-56F4AECD-DEE3-4DD5-8CA4-DDC174DA1A05

P2093

Q34317197-0081F048-6FA6-4FEE-BDD6-2955B5FB0C8D

Q34317197-3E46B8FC-3320-45E3-87D9-DF792425CBF2

Q34317197-46DFB233-7795-46A4-8A41-D6A255D1B0F0

Q34317197-49E2F845-4845-4AB1-AD4C-4D04256E47FD

Q34317197-6AA62724-4683-444C-95B0-7279918D1111

Q34317197-6DAF9345-E9A2-4C0A-BEB4-1E5D90587463

Q34317197-73271B1E-CF51-486F-AE82-6B06471E7F4F

Q34317197-750C926C-3424-47E9-9832-27FEA6FF9B96

Q34317197-B2542FEA-804C-4907-B9BD-35F1D3B01050

Q34317197-BFC2A3E7-E647-4905-BB6D-7EB554570103

P2860

Q34317197-031D648E-62FC-4CD2-84B0-1E26A7FD8877

Q34317197-03569C1C-37FD-45DE-B8CC-F3DE194A71A4

Q34317197-0A463E28-5F23-4201-AFB7-14982CD27E61

Q34317197-0AD277EA-83C4-4385-BB4B-2E281A7A53E7

Q34317197-118A3CA5-65EA-4CD5-B126-00D40DEFCF63

Q34317197-146976C7-84B3-4624-AB7C-B9B88D1FA6E2

Q34317197-1A7540C6-A92E-48A5-9516-99A91B4908FE

Q34317197-216C95E8-4489-41CD-8BCB-D5BC4A034136

Q34317197-22D1704C-0C18-4AE5-AD70-8C7FF509E7B4

Q34317197-27148600-6FD5-4A75-92BC-58172192AAE6

P304

Q34317197-27FFDD88-B722-4F7C-99B5-5E6F4E94F845

P31

Q34317197-714AF281-5318-4892-9E2C-804C292EF443

P356

Q34317197-761BCFC3-D435-42BB-A55A-A4873F8102C6

P407

Q34317197-A5D21051-5207-46B0-915F-0B59FB5CA4A6

P433

Q34317197-AA0F3614-5D6D-4995-9759-9B6D62871057

P478

Q34317197-C93F47FE-E77A-4FA5-9864-672227DF13A3

P50

Q34317197-0CE54D1E-42F8-4457-B8A5-C499399D26DA

Q34317197-6A92B56B-C924-4B55-828C-64EF68E12F8A

Q34317197-B2C6552A-7358-4386-9854-1015E77A5667

Q34317197-D67D1C63-D881-4154-84A3-46BD7955D6A6

P577

Q34317197-4D90833A-6D0F-476C-A95F-F014A580FE32

P5875

Q34317197-F222D07A-A241-42E6-8CA0-2A32F8243045

P698

Q34317197-36E4EDDA-8964-4340-AB0E-0F42AC7CC4B1

P932

Q34317197-F40D2038-87B2-4978-8587-A85067C4A04D

P356

ANNRHEUMDIS-2012-202450

P1433

Annals of the Rheumatic Diseases

P1476

Efficacy and safety of mavrilimumab in subjects with rheumatoid arthritis

@en

P2093

Alex Godwood

http://www.w3.org/2001/XMLSchema#string

Bing Wang

http://www.w3.org/2001/XMLSchema#string

EARTH Study Group

http://www.w3.org/2001/XMLSchema#string

Ehsanollah Esfandiari

http://www.w3.org/2001/XMLSchema#string

Fabio Magrini

http://www.w3.org/2001/XMLSchema#string

Guy Cavet

http://www.w3.org/2001/XMLSchema#string

Istvan Szombati

http://www.w3.org/2001/XMLSchema#string

Matthew A Sleeman

http://www.w3.org/2001/XMLSchema#string

Michael E Weinblatt

http://www.w3.org/2001/XMLSchema#string

Mykola Vatutin

http://www.w3.org/2001/XMLSchema#string

P2860

The chitinase 3-like protein human cartilage glycoprotein 39 (HC-gp39) stimulates proliferation of human connective-tissue cells and activates both extracellular signal-regulated kinase- and protein kinase B-mediated signalling pathways

Characteristics of a large cohort of patients with autoimmune pulmonary alveolar proteinosis in Japan.

The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis

Serum YKL-40 concentrations in patients with rheumatoid arthritis: relation to disease activity

The pathogenesis of rheumatoid arthritis

Analysis of complex biomarkers for human immune-mediated disorders based on cytokine responsiveness of peripheral blood cells.

Pulmonary alveolar proteinosis: progress in the first 44 years.

Mavrilimumab, a human monoclonal antibody targeting GM-CSF receptor-α, in subjects with rheumatoid arthritis: a randomised, double-blind, placebo-controlled, phase I, first-in-human study

Comparative study of KL-6, surfactant protein-A, surfactant protein-D, and monocyte chemoattractant protein-1 as serum markers for interstitial lung diseases.

Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial.

P304

1445-1452

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/ANNRHEUMDIS-2012-202450

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

72

http://www.w3.org/2001/XMLSchema#string

P50

Gerd-Rüdiger Burmester

Christopher D Kane

P577

2012-12-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

233908102

http://www.w3.org/2001/XMLSchema#string

P698

23234647

http://www.w3.org/2001/XMLSchema#string

P932

3756523

http://www.w3.org/2001/XMLSchema#string